ATE282041T1 - Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist - Google Patents

Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist

Info

Publication number
ATE282041T1
ATE282041T1 AT02706040T AT02706040T ATE282041T1 AT E282041 T1 ATE282041 T1 AT E282041T1 AT 02706040 T AT02706040 T AT 02706040T AT 02706040 T AT02706040 T AT 02706040T AT E282041 T1 ATE282041 T1 AT E282041T1
Authority
AT
Austria
Prior art keywords
aminomethylpyrrolochinazoline
thrombin receptor
receptor antagonist
par
methods
Prior art date
Application number
AT02706040T
Other languages
English (en)
Inventor
Bruce E Maryanoff
Han-Cheng Zhang
David F Mccomsey
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE282041T1 publication Critical patent/ATE282041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02706040T 2001-02-23 2002-01-29 Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist ATE282041T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27098801P 2001-02-23 2001-02-23
US10/059,707 US6740657B2 (en) 2001-02-23 2002-01-29 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
PCT/US2002/002489 WO2002068425A1 (en) 2001-02-23 2002-01-29 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE282041T1 true ATE282041T1 (de) 2004-11-15

Family

ID=26739081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02706040T ATE282041T1 (de) 2001-02-23 2002-01-29 Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist

Country Status (7)

Country Link
US (1) US6740657B2 (de)
EP (1) EP1370560B1 (de)
JP (1) JP2005500253A (de)
AT (1) ATE282041T1 (de)
DE (1) DE60201892T2 (de)
ES (1) ES2232735T3 (de)
WO (1) WO2002068425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20060142203A1 (en) * 2002-06-26 2006-06-29 Todd Hembrough Compositions and methods comprising protein activated receptor antagonists
US7262297B2 (en) * 2003-05-15 2007-08-28 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7226915B2 (en) * 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
EP1778652A2 (de) * 2004-08-20 2007-05-02 EntreMed, Inc. Zusammensetzungen und verfahren mit proteinaseaktivierten rezeptorantagonisten
WO2006046949A1 (en) * 2004-10-22 2006-05-04 Walter Reed Army Institute Of Research (Wrair) SYNTHESIS AND ANTIMALARIAL ACTIVITY OF PYRROLO[3,2-f]QUINAZOLINE-1,3- DIAMINE DERIVATIVES
US7253177B2 (en) 2004-10-22 2007-08-07 United States Of America As Represented By The Secretary Of The Army Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
EP2982756A1 (de) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamere zur Verwendung gegen Erkrankungen im Zusammenhang mit Autoantikörpern
CN115867354A (zh) * 2020-07-02 2023-03-28 普林斯顿大学理事会 具有抗癌活性的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118561A (en) 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
US4208520A (en) 1978-06-28 1980-06-17 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
US4451466A (en) 1982-07-02 1984-05-29 Shell Oil Company Use of pyrroloquinazolinediamines as pesticides
GB9123916D0 (en) * 1991-11-11 1992-01-02 Wellcome Found Heterocyclic compounds
WO2002012442A2 (en) * 2000-08-07 2002-02-14 Neurogen Corporation Heterocyclic compounds as ligands of the gabaa receptor

Also Published As

Publication number Publication date
EP1370560A1 (de) 2003-12-17
WO2002068425A1 (en) 2002-09-06
ES2232735T3 (es) 2005-06-01
US20020160963A1 (en) 2002-10-31
DE60201892T2 (de) 2005-11-03
DE60201892D1 (en) 2004-12-16
US6740657B2 (en) 2004-05-25
JP2005500253A (ja) 2005-01-06
EP1370560B1 (de) 2004-11-10

Similar Documents

Publication Publication Date Title
BRPI0414592A (pt) antagonistas de receptores de trombina
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
ATE525378T1 (de) Himbacinanaloga als thrombinrezeptorantagonisten
DE69940063D1 (de) Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE382353T1 (de) Substiuierte piperidine als melanocortinrezeptor- modulatoren
ATE411323T1 (de) Cgrp-rezeptorantagonisten
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
MY153719A (en) Prokineticin 1 receptor antagonists
ATE466860T1 (de) Cgrp-rezeptorantagonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60212146D1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
TW200716566A (en) Prokineticin 2 receptor antagonists
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
ATE334965T1 (de) Piperidinverbindungen als muscarinantagonisten
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
TW200531686A (en) Pharmaceutical compositions
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
NZ514696A (en) IL-8 receptor antagonists
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
MY143477A (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties